Tides 2017

April 30-May 3, 2017

May 2, 2017 - 4:15 pm-4:45 pm: Peptide Discovery, Preclinical and Clinical

Daniel Obrecht, Ph.D., Chief Scientific Officer and co-founder of Polyphor, will be a Speaker at the TIDES: Oligonucleotide and Peptide Therapeutics – April 30-May 3, 2017 in San Diego, USA. Dr. Obrecht's presentation entitled: " Discovery and Development of Novel Macrocycle Drugs: Outer Membrane Protein Targeting Antibiotics (OMPTA), A New Class with a Novel Mode of Action"

Polyphor has established two complementary, fully synthetic and proprietary macrocycle technologies: The presentation will cover the most recent developments and data from our break-through antibiotic research on a new series of macrocyclic peptides that have outstanding broad-spectrum activity against the most serious and relevant Gram-negative ESKAPE pathogens involved in hospital and community acquired infections. We have recently shown exceptional in vitro activity on the most recently emerging antibiotic-resistant strains, and in animal model studies we have shown excellent in vivo efficacy against relevant bacterial strains, including resistant strains. We will also give an update on our lead antibiotic Murepavadin (POL7080), which is a narrow-spectrum, targeted therapy for Pseudomonas infections in critically ill patients in the ICU. POL7080 has successfully completed Phase II and we are preparing the path forward for a Phase III registration trial. 


Daniel Obrecht Biography 

After a PhD in organic chemistry obtained from the University of Zurich (1983), D. Obrecht spent two years of postdoctoral studies working in Prof. R. E. Ireland’s group at the California Institute of Technology on the total synthesis of avermectin. He then joined the Central Research Laboratories of F. Hoffmann-La Roche in Basle (1985), where he worked on several drug discovery projects. In 1989 he started a project with the aim to find small molecule peptidomimetics of exposed protein epitopes. In 1993 he was awarded Roche Lecturer, and in 1994 he headed the combinatorial chemistry project at Roche Basle. End of 1996 he co-founded Polyphor with his brother Dr. Jean-Pierre Obrecht. The main expertise of D. Obrecht are synthetic organic chemistry with particular emphasis on macrocycles, medicinal chemistry and drug discovery. He is currently CSO at Polyphor and the author and co-author of 68 publications and 35 patents, including key patents on the Protein Epitope Mimetics (PEM) Technology and products, such as POL6014, POL7080, and POL6326.